No targetable driver mutations (epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK] and ROS‐1) and a programmed death‐ligand‐1 (PD‐L1) tumour proportion score of 25%–49% were shown. This evidence concerns the gene ALK and neoplasm.